• linkedin
  • Increase Font
  • Sharebar

    Sirolimus shows promise for posterior segment non-infectious uveitis

    Integrated study results consistently positive for intravitreal immunomodulatory drug


    Taper to safer dose

    “The data from SAKURA showing that intravitreal sirolimus allows patients to taper their oral corticosteroid to a safer dose without experiencing significant recurrence of their uveitis is quite promising,” Dr. Maturi said.

    Serious ocular adverse events in the SAKURA program were generally manageable and have been observed with intravitreal therapy. Rates of increased IOP in the sirolimus 440- and 44-mcg groups were 1.5% and 1.0%, respectively, and rates of cataract were 0.5% and 1.0%, respectively.


    Raj Maturi, MD

    E: [email protected]

    This article was adapted from a presentation at the 2017 meeting of the Association for Research in Vision and Ophthalmology. Dr. Maturi is a consultant to Santen.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';